CD276 (B7-H3) Monoclonal Antibody (MIH35), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: This monoclonal antibody reacts with mouse and human CD276 (also known as B7-H3), a type I transmembrane protein belonging to the B7 family of costimulatory proteins
• B7-H3 is expressed weakly on activated lymphocytes, macrophages, dendritic cells, nasal and airway epithelial cells, osteoblasts, and some tumor cell lines
• A soluble form of B7-H3 is also secreted by monocytes, dendritic cells, and activated T cells
• Although the biological role of this molecule remains controversial, recent studies have identified B7-H3 as the ligand for TREM-like 2 (TLT-2)
• Applications Reported: This MIH35 antibody has been reported for use in functional assays and flow cytometric analysis
• Applications Tested: This MIH35 antibody has been tested for blocking activity in mouse, as well as by flow cytometric analysis on transfected cell lines
• This can be used at 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3
• CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma
• Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon
• In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing
• CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.